Clinical Trials Logo

Genetic Skin Disease clinical trials

View clinical trials related to Genetic Skin Disease.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT03269474 Recruiting - Healthy Clinical Trials

Computational Drug Repurposing for All EBS Cases

Start date: November 28, 2017
Phase:
Study type: Observational

The study will compare gene expression differences between blistered and non-blistered skin from individuals with all subtypes of EB, as well as normal skin from non-EB subjects. State of the art computational analysis will be performed to help identify new drugs that might help all EB wound healing and reduce pain. Researchers will focus on drugs that have already been approved for treatment of other dermatologic or non-dermatologic diseases, and therefore be repurposed for treatment of EB. Drug development is a very expensive process taking decades for execution. Drug repurposing on the other hand, significantly reduces the cost and shortens the amount of time that is needed to bring effective treatments to clinical use. To date, there is no specific treatment targeting the physiology and immunologic response in EB patients during wound healing. Market availability of repurposed medications will provide all EB patients rapid access to treatments, thus improving their quality of life.